JP2000511771A - 病原性大腸菌関連タンパク質 - Google Patents

病原性大腸菌関連タンパク質

Info

Publication number
JP2000511771A
JP2000511771A JP09537532A JP53753297A JP2000511771A JP 2000511771 A JP2000511771 A JP 2000511771A JP 09537532 A JP09537532 A JP 09537532A JP 53753297 A JP53753297 A JP 53753297A JP 2000511771 A JP2000511771 A JP 2000511771A
Authority
JP
Japan
Prior art keywords
espa
polypeptide
coli
polynucleotide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP09537532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511771A5 (https=
Inventor
フィンレイ，ビー．，ブレット
スタイン，マルクス
ケニー，ブレンダン
Original Assignee
ユニバーシティー オブ ブリティッシュ コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ ブリティッシュ コロンビア filed Critical ユニバーシティー オブ ブリティッシュ コロンビア
Publication of JP2000511771A publication Critical patent/JP2000511771A/ja
Publication of JP2000511771A5 publication Critical patent/JP2000511771A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
JP09537532A 1996-04-23 1997-04-23 病原性大腸菌関連タンパク質 Ceased JP2000511771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1599996P 1996-04-23 1996-04-23
US60/015,999 1996-04-23
PCT/CA1997/000265 WO1997040063A2 (en) 1996-04-23 1997-04-23 Pathogenic escherichia coli associated protein espa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008233530A Division JP5058106B2 (ja) 1996-04-23 2008-09-11 病原性大腸菌関連タンパク質

Publications (2)

Publication Number Publication Date
JP2000511771A true JP2000511771A (ja) 2000-09-12
JP2000511771A5 JP2000511771A5 (https=) 2004-12-09

Family

ID=21774805

Family Applications (3)

Application Number Title Priority Date Filing Date
JP09537532A Ceased JP2000511771A (ja) 1996-04-23 1997-04-23 病原性大腸菌関連タンパク質
JP2008233530A Expired - Fee Related JP5058106B2 (ja) 1996-04-23 2008-09-11 病原性大腸菌関連タンパク質
JP2010043983A Pending JP2010132698A (ja) 1996-04-23 2010-03-01 病原性大腸菌関連タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008233530A Expired - Fee Related JP5058106B2 (ja) 1996-04-23 2008-09-11 病原性大腸菌関連タンパク質
JP2010043983A Pending JP2010132698A (ja) 1996-04-23 2010-03-01 病原性大腸菌関連タンパク質

Country Status (10)

Country Link
US (4) US6355254B1 (https=)
EP (1) EP0904288B1 (https=)
JP (3) JP2000511771A (https=)
KR (1) KR20000010667A (https=)
AU (1) AU2562897A (https=)
BR (1) BR9710433A (https=)
CA (1) CA2252372C (https=)
DK (1) DK0904288T3 (https=)
ES (1) ES2389625T3 (https=)
WO (1) WO1997040063A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522638A (ja) * 2010-03-23 2013-06-13 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｉｉｉ型分泌機構の阻害剤の同定方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
BR9710433A (pt) 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica
US6204004B1 (en) * 1997-03-21 2001-03-20 University Of Maryland, Baltimore Immunodiagnostic test for enterohemorrhagic Escherichia coli infection
US7208574B1 (en) 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
WO1999045136A1 (en) * 1998-03-05 1999-09-10 University Of British Columbia Methods for assaying type iii secretion inhibitors
US6342352B1 (en) 1998-04-24 2002-01-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of detecting shigella and shigella mxiM DNA
US6136542A (en) * 1998-05-13 2000-10-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
US6696249B1 (en) 1998-05-13 2004-02-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
WO2001073440A2 (de) * 2000-03-28 2001-10-04 Schebo Biotech Ag Nachweis von diarrhogenen e.coli-keimen
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
BRPI0415816A (pt) 2003-10-31 2006-12-26 Univ British Columbia composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
GB0411624D0 (en) * 2004-05-25 2004-06-30 Imp College Innovations Ltd Products and uses thereof
JP5151477B2 (ja) 2005-04-28 2013-02-27 日立金属株式会社 半導体磁器組成物とその製造方法
WO2008133659A2 (en) 2006-11-29 2008-11-06 Tufts University Eschericia coli mutants and methods of use thereof
WO2009032978A2 (en) * 2007-09-07 2009-03-12 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP2012522522A (ja) 2009-04-06 2012-09-27 ユニバーシティー オヴ サスカチュワン 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
US20110229512A1 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15999A (en) 1856-10-28 Improved projectile for ordnance
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
BR9710433A (pt) * 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522638A (ja) * 2010-03-23 2013-06-13 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｉｉｉ型分泌機構の阻害剤の同定方法

Also Published As

Publication number Publication date
US20060292180A1 (en) 2006-12-28
BR9710433A (pt) 1999-10-05
US20110003339A1 (en) 2011-01-06
CA2252372A1 (en) 1997-10-30
JP2010132698A (ja) 2010-06-17
CA2252372C (en) 2010-06-29
US20020115829A1 (en) 2002-08-22
ES2389625T3 (es) 2012-10-29
JP5058106B2 (ja) 2012-10-24
WO1997040063A3 (en) 1998-03-26
US7078193B2 (en) 2006-07-18
DK0904288T3 (da) 2012-09-24
AU2562897A (en) 1997-11-12
US8021861B2 (en) 2011-09-20
EP0904288B1 (en) 2012-06-13
JP2009022294A (ja) 2009-02-05
US6355254B1 (en) 2002-03-12
EP0904288A2 (en) 1999-03-31
US7214499B2 (en) 2007-05-08
KR20000010667A (ko) 2000-02-25
WO1997040063A2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
JP5058106B2 (ja) 病原性大腸菌関連タンパク質
Agin et al. Identification of a family of intimins common to Escherichia coli causing attaching-effacing lesions in rabbits, humans, and swine
US12599637B2 (en) Genetically modified Lactobacillus and uses thereof
US20080213285A1 (en) Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
JP2009173667A (ja) 病原菌のｔｉｒ遺伝子によってコードされる、病原菌の宿主の膜受容体、ｈｐ９０
JP4189031B2 (ja) グラム陰性菌からの異型ｏ抗原の高レベルの発現に有用な生ワクチン担体株と生ワクチンとして使用するためのその誘導体
Ludwig et al. Haemolysins of Escherichia coli
US20040131624A1 (en) Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type lll secretion pathway of a gram-negative bacteria.
US7208574B1 (en) Host receptor for pathogenic bacteria
MXPA98008795A (es) Proteina asociada con escherichia coli patogena
CN1222937A (zh) 致病性大肠杆菌相关蛋白
Peterson Characterization of Escherichia coli Enterohemolysin 1
Ala'Aldeen et al. CapA, an autotransporter protein of
Gray-Owen et al. Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria
Henderson Development of new approaches to identify and characterise Campylobacter jejuni genes
O'Driscoll Molecular analysis of virulence mechanisms associated with adherent-invasive Escherichia coli (AIEC)
Emery Molecular genetic characterisation of the campylobacter jejuni htra-regx/y locus
O'Driscoll Molecular analysis of virulence mechanisms associated with adherent
HK1056369B (en) Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type iii secretion pathway of a gram-negative bacteria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080707

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20070220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080811

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081216